Economic Burden of the Adverse Events During Treatment of Metastatic Breast Cancer (mBC) HR-/HER2+ Patients in the Brazilian Private Healthcare System
Author(s)
Gisele L. V. Araujo, MSc1, Henrique Tortele, BS1, Thiago B. Oliveira, PhD2, Fabiana Sanches, MD, MBA2, Caio M. Huerta, BS1, Leandro Santos, BS1, Fabiano A. Costa, MD3.
1Market Access, Daiichi Sankyo, São Paulo, Brazil, 2Medical, Daiichi Sankyo, São Paulo, Brazil, 3COE Ensino e Pesquisa, São José dos Campos, Brazil.
1Market Access, Daiichi Sankyo, São Paulo, Brazil, 2Medical, Daiichi Sankyo, São Paulo, Brazil, 3COE Ensino e Pesquisa, São José dos Campos, Brazil.
OBJECTIVES: Treatment of mBC leads to various adverse events (AEs) which burden patients and the healthcare system. This study will identify the cost of managing grade 3 or higher AEs associated with mBC HR-/HER2+ treatment.
METHODS: The treatments were selected based on the NCCN 2025 and SBOC 2024 guidelines, excluding target therapies. Then, AE grade ≥ 3 with frequency of ≥ 2% for each therapy was identified. AE management costs were estimated using a micro-costing approach, information from MASCC, MOC, and scientific articles to determine the procedures required to manage each AE per patient. Procedures costs were extracted from the D-TISS database, CBHPM and PRÓSER reference price list and CMED drug list price. The Unidas Report (2023) was used for daily inpatient data, while Borba et al. (2023) was referenced for daily outpatient data. The prices were adjusted according to the IPCA 2024. All data was validated by KOL.
RESULTS: Based on chemotherapy and ADCs treatment options recommended by the guidelines for mBC HR-/HER2+, a total of 28 grade ≥3 AEs were identified. The average cost of managing these AEs was US$ 962.22 (range: US$ 43.04 to US$ 6,320.11). Hematological AEs had a higher mean management cost (US$ 1,511.00) compared to non-hematological AEs (US$ 779.29). The five AEs with the highest management costs were: neutropenic fever (US$ 6,320.11), urinary tract infection (US$ 2,816.83), anemia (US$ 2,222.59), respiratory infection (US$ 1,849.59), and pain (US$ 1,839.78). Conversely, the five AEs with the lowest management costs were: decreased appetite (US$ 89.18), rash (US$ 77.81), lymphopenia (US$ 70.49), hand-foot syndrome (US$ 60.36), and hyperglycemia (US$ 43.04). *Exchange: US$ 1.00 = R$ 5.60
CONCLUSIONS: A significant cost associated with managing grade ≥3 AEs was identified, especially with hematological AEs from the perspective of the Brazilian private healthcare system.
METHODS: The treatments were selected based on the NCCN 2025 and SBOC 2024 guidelines, excluding target therapies. Then, AE grade ≥ 3 with frequency of ≥ 2% for each therapy was identified. AE management costs were estimated using a micro-costing approach, information from MASCC, MOC, and scientific articles to determine the procedures required to manage each AE per patient. Procedures costs were extracted from the D-TISS database, CBHPM and PRÓSER reference price list and CMED drug list price. The Unidas Report (2023) was used for daily inpatient data, while Borba et al. (2023) was referenced for daily outpatient data. The prices were adjusted according to the IPCA 2024. All data was validated by KOL.
RESULTS: Based on chemotherapy and ADCs treatment options recommended by the guidelines for mBC HR-/HER2+, a total of 28 grade ≥3 AEs were identified. The average cost of managing these AEs was US$ 962.22 (range: US$ 43.04 to US$ 6,320.11). Hematological AEs had a higher mean management cost (US$ 1,511.00) compared to non-hematological AEs (US$ 779.29). The five AEs with the highest management costs were: neutropenic fever (US$ 6,320.11), urinary tract infection (US$ 2,816.83), anemia (US$ 2,222.59), respiratory infection (US$ 1,849.59), and pain (US$ 1,839.78). Conversely, the five AEs with the lowest management costs were: decreased appetite (US$ 89.18), rash (US$ 77.81), lymphopenia (US$ 70.49), hand-foot syndrome (US$ 60.36), and hyperglycemia (US$ 43.04). *Exchange: US$ 1.00 = R$ 5.60
CONCLUSIONS: A significant cost associated with managing grade ≥3 AEs was identified, especially with hematological AEs from the perspective of the Brazilian private healthcare system.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE367
Topic
Economic Evaluation, Medical Technologies, Real World Data & Information Systems
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology